Table 2: IMK ATP levels in the patients who experienced late clinical events.

AgeGenderEtiology of LDLTClinical eventsMonths after LDLT Tacrolimus
concentration
(ng/mL)
C/D ratio
(ng/mL/mg/kg/day)
IMK
ATP levels (ng/mL)

46FLCPhlegmon89.5 9.899.76 112
60MLCCholangitis103.3 8.4478.80 113
58MHCV, HCCRHC57.9 6.343.31 137
20FPSCCholangitis92.1 3.9105.86 141
60MHCVRHC27.1 8.2259.12 149
61FLC, HCCUTI34.9 10229.00 166
68MHCV, HCCRHC52.4 7.9166.95 205
62FHCV, HCCRHC86.3 8.6237.79 215
52MPBCPneumonia55.5 2.7316.44 222
50MHCVRHC17.3 2.0128.80 322

51MPBCRejection38.8 2.543.25 569
43MFHRejection45.4 8.4171.57 683
58FHBV, HCCRejection19.9 9.9207.90 692
25MBARejection104.7 6.8113.33 709

IMK: ImmuKnow, LDLT: living donor liver transplantation, C/D ratio: concentration/dosage ratio, LC: liver cirrhosis, HCV: hepatitis C virus, HCC: hepatocellular carcinoma, PSC: primary sclerosing cholangitis, PBC: primary biliary cirrhosis, HBV: hepatitis B virus, FH: fulminant hepatitis, BA: biliary atresia, RHC: recurrence of hepatitis C, UTI: urinary tract infection.